Claims for Patent: 9,539,251

Summary for Patent: 9,539,251

Title:	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Abstract:	The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Inventor(s):	Sampath; Deepak (South San Francisco, CA), Klein; Christian (Iffeldorf, DE), Fairbrother; Wayne John (South San Francisco, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH)
Application Number:	14/020,761
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,539,251
Patent Claims:	1. A method for the treatment of a cancer in a human in need thereof comprising co-administering to said human an effective amount of a GA101 antibody and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4((2-(4-chlorophenyl)-4,4-dimethy- lcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran- -4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, followed by (i) administering to said human an effective amount of said GA101 antibody alone in the absence of 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeth- ylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyra- n-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, or (ii) administering to said human an effective amount of 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4(2-(4-chlorophenyl)-4,4-dimethyl- cyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-- 4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof alone in the absence of said GA101 antibody for one or more dosing periods, wherein the cancer is a CD20-expressing cancer. 2. A method for the treatment of a cancer in a human in need thereof comprising co-administering an effective amount of a GA101 antibody and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4(4-((2-(4-chlorophenyl)-4,4-dime- thylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-py- ran-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, followed by (i) administering to said human an effective amount of said GA101 antibody alone in the absence of 2-(1H-pyrrolo[2,3 ]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)m- ethyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)- phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days, or (ii) administering to said human an effective amount of 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeth- ylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyra- n-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof alone in the absence of said GA101 antibody for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days, wherein the cancer is a CD20-expressing cancer. 3. The method of claim 1, comprising co-administering an effective amount of said GA101 antibody once every dosing period during the co-administration and 2-(1H-pyrrolo[2,3-b]pyridin- 5-yloxy)-4-(4-(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)pipe- razin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulf- onyl)benzamide or a pharmaceutically acceptable salt thereof one, two or three times a day during the co-administration for one or more dosing periods, followed by administering an effective amount of said GA101 antibody alone once every dosing period for 1, 2, 3, 4, 5 or 6 dosing periods. 4. The method of claim 1, comprising co-administering an effective amount of said GA101 antibody once every dosing period during the co-administration and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeth- ylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyra- n-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof one, two or three times a day during the co-administration for one or more dosing periods, followed by administering an effective amount of 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeth- ylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyra- n-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof alone one, two or three times a day for 1, 2, 3, 4, 5 or 6 dosing periods. 5. The method of claim 4, wherein the effective amount of said GA101 antibody is from about 500 mg to about 3000 mg and the effective amount of 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4((2-(4-chlorophenyl)-4,4-dime- thylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-py- ran-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof is from about 20 mg to about 500 mg. 6. The method of claim 4, wherein the effective amount of said GA101 antibody is 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg, and the effective amount of 2-(1H-pyrrolo [2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-- enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methyl- amino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof is 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 mg. 7. The method of claim 1, wherein said GA101antibody and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeth- ylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyra- n-4-yl)methylamino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof are co-administered sequentially during each dosing period during co-administration, and each dosing period is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days. 8. The method of claim 1, wherein said GA101antibody is an anti human CD20 antibody comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:3, an HVR-L1 comprising the amino acid sequence of SEQ ID NO:4, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:6. 9. The method according to claim 8, wherein said GA101 antibody further comprises a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:8. 10. The method according to any one of claims 1-7 wherein said GA101 antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 9 and a light chain having the amino acid sequence of SEQ ID NO: 10. 11. The method of claim 1, wherein the GA101 antibody is known as obinutuzumab. 12. The method of claim 1, wherein the CD20-expressing cancer is a lymphoma or a leukemia. 13. The method according to claim 12, wherein the CD20-expressing cancer is a leukemia, and wherein the leukemia is chronic lymphocytic leukemia. 14. The method according to claim 13, wherein the human is suffering from relapsed or refractory or previously untreated chronic lymphocytic leukemia.